テネシーにおける濾胞性リンパ腫の臨床試験
テネシー内の拠点で、濾胞性リンパ腫に関する19件の研究が参加者を募集しています。
テネシー内の都市
公式研究テキスト（英語）
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT03460977A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Tennesse Oncology Chattanooga Downtown, Chattanooga
- Tennessee Oncology, Pllc Nashville, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- SCRI Oncology Partners ( Site 7000), Nashville
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07634471A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- SCRI Oncology Partners ( Site 0100), Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07519772A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Nashville
被験者募集中第3相
18歳〜130歳 · 全性別 · 2026/09/21更新 · NCT06549595Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06526793Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Tennessee Oncology, Nashville
被験者募集中第3相
12歳〜100歳 · 全性別 · 2026/09/11更新 · NCT06784752A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Vanderbilt University Medical Center, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06091254Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Vanderbilt University/Ingram Cancer Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06860594SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Vanderbilt-Ingram Cancer Center, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Vanderbilt University Medical Center, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
- Vanderbilt University Medical Center, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06651177Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
- Tennessee Oncology, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/24更新 · NCT07121946The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Tennessee Oncology, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/20更新 · NCT04830137SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。